Shares of Xenetic Biosciences (NASDAQ:XBIO) were down 95.4% on Monday . The stock traded as low as $2.74 and last traded at $5.57. Approximately 131,237 shares traded hands during trading, a decline of 71% from the average daily volume of 452,366 shares. The stock had previously closed at $2.85.

About Xenetic Biosciences

Xenetic Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of biologic drugs and oncology therapeutics. Its lead proprietary technology is PolyXen, a platform technology for the treatment of anemia in chronic kidney disease patients. The company's lead drug candidate is XBIO-101, a small-molecule interferon inducer for the treatment of progesterone receptor negative endometrial cancer and triple negative breast cancer.

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with's FREE daily email newsletter.